These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 30828862)
1. Topical sirolimus as an effective treatment for a deep neurofibroma in a patient with neurofibromatosis type I. Malhotra N; Levy JMS; Fiorillo L Pediatr Dermatol; 2019 May; 36(3):360-361. PubMed ID: 30828862 [TBL] [Abstract][Full Text] [Related]
2. Pilot study for the treatment of cutaneous neurofibromas in neurofibromatosis type 1 patients using topical sirolimus gel. Wataya-Kaneda M; Watanabe Y; Nakamura A; Yamamoto K; Okada K; Maeda S; Nimura K; Saga K; Katayama I J Am Acad Dermatol; 2023 Apr; 88(4):877-880. PubMed ID: 36334988 [No Abstract] [Full Text] [Related]
4. Occult neurofibroma and increased S100 protein in the skin of patients with neurofibromatosis type 1: new insight to the etiopathomechanism of neurofibromas. Karvonen SL; Kallioinen M; Ylä-Outinen H; Pöyhönen M; Oikarinen A; Peltonen J Arch Dermatol; 2000 Oct; 136(10):1207-9. PubMed ID: 11030766 [TBL] [Abstract][Full Text] [Related]
5. Prevalence and clinicopathological characteristics of lipomatous neurofibromas in neurofibromatosis 1: An investigation of 229 cutaneous neurofibromas and a systematic review of the literature. Rozza-de-Menezes RE; Brum CAI; Gaglionone NC; de Sousa Almeida LM; Andrade-Losso RM; Paiva BVB; Faveret PLS; da Silva AV; Siqueira OHK; Riccardi VM; Cunha KS J Cutan Pathol; 2018 Oct; 45(10):743-753. PubMed ID: 29959804 [TBL] [Abstract][Full Text] [Related]
6. Comparative Effects of Topical 0.2% Sirolimus for Angiofibromas in Adults and Pediatric Patients with Tuberous Sclerosis Complex. Lee YI; Lee JH; Kim DY; Chung KY; Shin JU Dermatology; 2018; 234(1-2):13-22. PubMed ID: 29925060 [TBL] [Abstract][Full Text] [Related]
7. Pseudoatrophic macules associated with neurofibromatosis-1. Chiu CS; Wang JD; Yen CY; Chen YJ; Shen JL Pediatr Dermatol; 2009; 26(2):231-2. PubMed ID: 19419486 [TBL] [Abstract][Full Text] [Related]
8. Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials. Cannon A; Sarin KY; Petersen AK; Pichard DC; Wolters PL; Erickson G; Lessing AJ; Li P; Röhl C; Rosser T; Widemann BC; Blakeley JO; Plotkin SR Clin Trials; 2024 Feb; 21(1):67-72. PubMed ID: 37269078 [TBL] [Abstract][Full Text] [Related]
9. Sirolimus improves pain in NF1 patients with severe plexiform neurofibromas. Hua C; Zehou O; Ducassou S; Minard-Colin V; Hamel-Teillac D; Wolkenstein P; Valeyrie-Allanore L Pediatrics; 2014 Jun; 133(6):e1792-7. PubMed ID: 24864177 [TBL] [Abstract][Full Text] [Related]
11. Considerations for development of therapies for cutaneous neurofibroma. Verma SK; Riccardi VM; Plotkin SR; Weinberg H; Anderson RR; Blakeley JO; Jarnagin K; Lee J Neurology; 2018 Jul; 91(2 Suppl 1):S21-S30. PubMed ID: 29987132 [TBL] [Abstract][Full Text] [Related]
12. Bilateral cranio-orbital neurofibromas in a 16-year-old child with neurofibromatosis 1. Li P; Yang Z; Wang Z; Liu P Neurol India; 2016; 64(4):835-6. PubMed ID: 27381153 [No Abstract] [Full Text] [Related]
13. Cutaneous angiomyolipoma masquerading as a neurofibroma in a child with neurofibromatosis type 1: a case report. Carrau D; Kahwash S; Pearson G Pediatr Dermatol; 2015; 32(3):423-4. PubMed ID: 25640861 [TBL] [Abstract][Full Text] [Related]
14. Neurofibroma of the breast in a boy with neurofibromatosis type 1. Murat A; Kansiz F; Kabakus N; Kazez A; Ozercan R Clin Imaging; 2004; 28(6):415-7. PubMed ID: 15531141 [TBL] [Abstract][Full Text] [Related]
15. Cutaneous neurofibromas in Neurofibromatosis type I: a quantitative natural history study. Cannon A; Chen MJ; Li P; Boyd KP; Theos A; Redden DT; Korf B Orphanet J Rare Dis; 2018 Feb; 13(1):31. PubMed ID: 29415745 [TBL] [Abstract][Full Text] [Related]
16. Cervical segment nervus vagus neurofibroma with associated neurofibromatosis type 1: a case report. Guler AK; Gunaldi O; Alis H; Tugcu B; Tanriverdi O; Colluoglu B Minim Invasive Neurosurg; 2009 Oct; 52(5-6):246-9. PubMed ID: 20077367 [TBL] [Abstract][Full Text] [Related]
17. Effect of NFX-179 MEK inhibitor on cutaneous neurofibromas in persons with neurofibromatosis type 1. Sarin KY; Bradshaw M; O'Mara C; Shahryari J; Kincaid J; Kempers S; Tu JH; Dhawan S; DuBois J; Wilson D; Horwath P; de Souza MP; Powala C; Kochendoerfer GG; Plotkin SR; Webster GF; Le LQ Sci Adv; 2024 May; 10(18):eadk4946. PubMed ID: 38691597 [TBL] [Abstract][Full Text] [Related]
18. Topical delivery of mitogen-activated protein kinase inhibitor binimetinib prevents the development of cutaneous neurofibromas in neurofibromatosis type 1 mutant mice. Coulpier F; Pulh P; Oubrou L; Naudet J; Fertitta L; Gregoire JM; Bocquet A; Schmitt AM; Wolkenstein P; Radomska KJ; Topilko P Transl Res; 2023 Nov; 261():16-27. PubMed ID: 37331503 [TBL] [Abstract][Full Text] [Related]
20. Melanocytic nevi are associated with neurofibromas in neurofibromatosis, type I, but not sporadic neurofibromas: a study of 226 cases. Ball NJ; Kho GT J Cutan Pathol; 2005 Sep; 32(8):523-32. PubMed ID: 16115049 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]